Wegovy's Pediatric Push: A Crucial Test for Novo Nordisk The recent success of Novo Nordisk's STEP Young trial has sent shockwaves through the pharmaceutical industry.
The trial tested semaglutide in young children with obesity, and the data is impressive – 40. 4% of participants who received the treatment were no longer classified as having obesity after 68 weeks.
However, this achievement is just one piece of a larger puzzle, raising questions about Novo Nordisk's long term strategy and its ability to innovate in a crowded market. A New Growth Avenue?